AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

This study is testing whether adding an immunotherapy drug (AK104, a dual checkpoint inhibitor) to standard chemotherapy before and after surgery can improve outcomes for patients with early-stage, surgically removable non-small cell lung cancer (NSCLC). **You may be eligible if...** - You have Stage II or IIIA non-small cell lung cancer that can be surgically removed - You have not previously received any treatment for this lung cancer - You have at least one measurable tumor lesion - You are in good overall health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You have a mixed lung cancer type (NSCLC + small cell) - You have had another active cancer in the past 3 years - You have known autoimmune disease - You have been on immunosuppressant medications recently Talk to your doctor to see if this trial is right for you.